Wall Street always "overdoses" on one side or the other.
You ask what TCLN might be worth. How about this scenario. I don't think its' impossible, or even far fetched.
For sake of arguement bio-tech companies with successful products can trade at 10x sales. Assume 40,000,000 issued and out which gives plenty of leeway from the 28MM out now. Plenty of room for conversion of the last issuance and then some. Dr. Swift, from Hanifen, says TCLN might exceed $300,000,000 of U.S. sales from LYM-1. I'm going to assume $150,000,000 world wide sales, so if the drug is approved my estimate is conservative. I'm afraid to put the numbers in writing so multiply worldwide sales x 10 and divide by 40MM. That equals $30+per share and thats just for Lym-1. That doesn't include TNT, VE, VTA, and everything else we don't know about. That's enough to make me happy.
Does that make you happy, too? |
